SCHEMBL1750145

SCHEMBL1750145

CC(=O)NCc1ccc(Cl)c(C=O)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
ALDH1A1 P00352 3/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HPGD P15428 1/20 0.43
S1PR4 O95977 1/20 0.41
HSP90AA1 P07900 1/20 0.41
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
NOTUM Q6P988 1/20 0.39
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1751039 0.86 TSHR (0.69) TSHRALDH1A1KMT2ASMN1; SMN2HPGD
SCHEMBL1750878 0.85 TSHR (0.48) TSHRALDH1A1RAB9AKMT2ASMN1; SMN2
SCHEMBL1751947 0.85 LMNA (0.55) ALDH1A1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL16671183 0.84 ERCC1 (0.56) TSHR
SCHEMBL16670980 0.84 PTGES (0.49) TSHRSMN1; SMN2HDAC6HPGD
SCHEMBL5724113 0.82 TSHR (0.72) TSHRALDH1A1MAPTPOLBRAB9A
SCHEMBL29952190 0.80 TSHR (0.54) TSHRSMN1; SMN2HDAC1HDAC6L3MBTL1
SCHEMBL1751352 0.80 ERCC1 (0.51) ALDH1A1MAPTPOLBRAB9AKMT2A
SCHEMBL1751145 0.79 TSHR (0.41) TSHRRAB9ASMN1; SMN2HPGDLMNA
SCHEMBL1750933 0.78 TSHR (0.53) TSHRALDH1A1MAPTPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968720-B2 Secondary amines as renin inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2011-06-28 US disclosed
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES BEZENCON OLIVIER 2010-12-23 US disclosed
US-7799805-B2 Piperidine carboxylic acid amide derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-21 US disclosed
US-20090176823-A1 Secondary Amines as Renin Inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2009-07-09 US disclosed
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives ACTELION PHARMACEUTICALS LTD (CH) 2008-09-04 US disclosed
EP-1893578-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-03-05 EP disclosed
WO-2006129237-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives REN, ACE, AGTR2 TSHR 3578/4885ALDH1A1 387/4885MAPT 2131/4885
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES REN, ACE, AGTR2 TSHR 3666/4885ALDH1A1 313/4885MAPT 1742/4885
US-20090176823-A1 Secondary Amines as Renin Inhibitors REN, ACE, AGTR1 TSHR 1994/4885ALDH1A1 941/4885MAPT 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.